explore -WSS

explore

author：leisure time 2025-09-02 22:08:10 - browse：28596

Andrea Coravos, managing director at ICON, speaks at the STAT Breakthrough Summit West in San Francisco Thursday as Ida Sim, chief research informatics officer at UCSF, looks on. Sarah Gonzalez for STAT

Just because the Food and Drug Administration has given the Apple Watch and other wearable devices the OK to market the health benefits of their tracking and algorithms doesn’t mean that the data they generate are useful for either patients or their doctors, experts said Thursday at the STAT Breakthrough Summit West in San Francisco.

“Yesterday, I saw a patient with type 2 diabetes who has a continuous glucose monitor, and so she’s been tracking her blood sugar every five minutes,” said Ida Sim, a primary care physician and chief research informatics officer at the University of California, San Francisco. “[I] sat with her for almost an hour yesterday. I couldn’t get to her CGM data — she had it on her phone, but the report goes into a website that I didn’t have the login to, and it hadn’t been downloaded into my electronic medical record. So all this tracking data, I didn’t have it.”

Not only do clinicians not have the ability to access data that their patients want to use to guide their care, but primary care doctors often don’t know how to interpret that firehose of data, said Sim. She asked some of her endocrinology research colleagues how they use that data and they explained the calculations needed to create biomarker metrics from them. That made the data largely useless to her as a doctor, and it was frustrating.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： CDC concerned about possible undetected monkeypox spread in U.K.

focus

WSS

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Cassava Sciences’ Alzheimer’s clinical trials should be halted

FDA clears Verve to begin U.S. study of gene

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Why a market frenzy over new weight loss drugs defies logic

Ask STAT: What do you want to know about ChatGPT in medicine?

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Drug repurposing or repositioning? The language matters

In areas with more Black doctors, Black people live longer

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth, Optum discontinue NaviHealth name

Anesthesiologist group: stop taking Ozempic before surgery

Colonoscopy at 40? Study finds a possible benefit

Affirmative action in medical school literally saved lives

STAT's guide to the next generation of CAR

Tori Bowie and the unacceptable rates of Black maternal death

Questions loom on AstraZeneca cancer drug as safety concerns ebb

hotspot

Roche acquires Telavant from Roivant, adding experimental IBD treatment

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

STAT Summit: Meghan O’Rourke on making chronic illness visible

Gene therapy has helped boys walk. Can scientists keep it that way?

3 hurdles to bringing medical devices to the U.S. market

Merck, Daiichi strike cancer drug pact worth up to $22 billion

focus

leisure time

Wikipedia

Wikipedia